MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

por Eleveld, Thomas F., Vernooij, Lindy, Schild, Linda, Koopmans, Bianca, Alles, Lindy K., Ebus, Marli E., Dandis, Rana, van Tinteren, Harm, Caron, Huib N., Koster, Jan, van Noesel, Max M., Tytgat, Godelieve A. M., Eising, Selma, Versteeg, Rogier, Dolman, M. Emmy M., Molenaar, Jan J.
Publicado 2023

Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma

por van den Boogaard, Marlinde L., Oka, Rurika, Hakkert, Anne, Schild, Linda, Ebus, Marli E., van Gerven, Michael R., Zwijnenburg, Danny A., Molenaar, Piet, Hoyng, Lieke L., Dolman, M. Emmy M., Essing, Anke H. W., Koopmans, Bianca, Helleday, Thomas, Drost, Jarno, van Boxtel, Ruben, Versteeg, Rogier, Koster, Jan, Molenaar, Jan J.
Publicado 2021

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

por Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E., Licciardello, Marco P., Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M., Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S., Christova, Rossitza, Boysen, Gunther, Richards, Mark W., Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A., De Bono, Johann, Gray, Nathanael S., Blagg, Julian, Robinson, Simon P., Eccles, Suzanne A., Zheleva, Daniella, Bradner, James E., Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y., Chesler, Louis
Publicado 2020